Skip to main content

ERC

News

Participate
Products
- Gliovac/ERC1671
Media
- News
- Publications
About
Contact

News Publications

09

Apr

2020

ERC covid product launch against covid19

ERC Worldwide today announced the launch of the Company’s development program for its therapeutic and prophylactic vaccine against the new coronavirus SARS-CoV-2. The technology is based on ERC’s Gliovac/ERC1671 glioblastoma vaccine platform currently in an FDA approved clinical trial in the US.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Cookie and Privacy Policy for more details.

Close

Made byKonnu

Cookie and Privacy Policy Terms & Conditions

Top